• Product NameNilotinib (AMN-107)
• Brief DescriptionInhibitors
• Purification99.00%
• Biological ActivityNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec?), another tyrosine kinase inhibitor currently used as a first-line treatment.
• Target NameBcr-Abl inhibitor
• CAS No. 641571-10-0
• Calculated MW 529.52
• Formulation C28H22F3N7O
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC1=CN(C=N1)C1=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=CC(=C1)C(F)(F)F
  Pathways:Angiogenesis; Cytoskeletal Signaling
  Receptor:Bcr-Abl
  Boling pt:
  Melting pt:
  Solubility:DMSO: 27 mg/mL (50.98 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Maekawa T, et al. Int J Clin Oncol. 2007 Oct;12(5):327-40.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting